Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)

NCT02825914 is registered in ClinicalTrials.gov with University of Aarhus as lead sponsor.

NCT NCT02825914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02825914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)
Lead sponsor
University of Aarhus
Phase
Not applicable
Overall status
Completed
Start date
September 1, 2016
Completion date
October 1, 2019
Enrollment
80 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colitis, ulcerative, inflammatory bowel diseases